



ASH 2023

65th ASH Annual Meeting and Exposition

December 9–12, 2023
San Diego, US



TOP ABSTRACTS

To help navigate the exciting content being presented at the 65th ASH Annual Meeting and Exposition, we have provided recommendations for the top abstracts to look out for in acute lymphoblastic leukemia (ALL).

ASH 2023: Top abstracts in ALL

December 9–12, 2023

Frontline and emerging therapies for ALL	
Abstract	Title
419 View	RPT1G: A 1st-in-class small molecule NAMPT inhibitor as a novel therapeutic for acute lymphocytic leukemia
517 View	Risk-adjusted therapies yield equivalent outcomes for adolescents and young adults (AYAs) treated for newly diagnosed t-cell acute lymphoblastic leukemia (t-all) on Children's Oncology Group (COG) studies AALL0434 and AALL123
823 View	Outcome of infants treated on total therapy for infants with acute lymphoblastic leukemia I: results from a non-randomized multi-center study
824 View	Patients with down syndrome and high-risk B-acute lymphoblastic leukemia demonstrate improved outcomes on a modified chemotherapy regimen: a report from Children's Oncology Group study AALL1131
825 View	Pediatric patients with high-risk b-cell all in first complete remission may benefit from less toxic immunotherapy with blinatumomab – results from randomized controlled phase 3 trial AIEOP-BFM all 2017
826 View	Sequential chemotherapy and blinatumomab to improve minimal residual disease in adult ph- b-lineage acute lymphoblastic leukemia. Final results of the phase II gimema LAL2317 trial
827 View	Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for patients with newly diagnosed philadelphia chromosome-positive acute lymphoblastic leukemia: early results from a phase II study
828 View	CNS irradiation in adult de novo B-precursor ALL / LBL: results of the randomized GMALL trial 08/2013 indicate potential antileukemic efficacy
891 View	Dasatinib and CAR-T cell therapy for newly diagnosed ph-positive acute lymphoblastic leukemia in adults
961 View	Feasibility and outcome of post-induction therapy incorporating dasatinib for patients with newly diagnosed ABL-class fusion B-lymphoblastic leukemia (ABL-class fusion B-all): Children's Oncology Group AALL1131
962 View	Frontline consolidation with nelarabine for adults with high-risk t-cell acute lymphoblastic leukemia. Results of the GRAAll-2014/T Atriall phase 2 study
963 View	Nelarabine (nel), pegylated asparaginase (peg) and venetoclax (ven) incorporated to HCVD chemotherapy in the frontline treatment of adult patients with T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/T-LBL)

964 View	Dose reduced chemotherapy in sequence with blinatumomab for newly diagnosed older patients with Ph/BCR::ABL negative B-precursor adult lymphoblastic leukemia (ALL): preliminary results of the GMALL bold trial
1498 View	Efficacy and safety of recombinant erwinia asparaginase (JZP458) in acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL): complete follow-up of the Children's Oncology Group (COG) AALL1931 study
1499 View	Long-term follow up for SWOG 1318: combination of dasatinib, prednisone, and blinatumomab for older patients with Philadelphia-chromosome (Ph) positive acute lymphoblastic leukemia (ALL)
1500 View	Impact of high-risk cytogenetics (HR-CTG) on the outcome of newly diagnosed adult patients with Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) treated with frontline blinatumomab (blina) and/or inotuzumab ozogamicin (ino) containing hypercvad (HCVAD) therapy
1504 View	Frontline combination of 3rd generation TKI olverembatinib and blinatumomab for Ph+/Ph-like all patients
1510 View	Chemotherapy-sparing induction followed by consolidation and maintenance with blinatumomab and concurrent oral tyrosine kinase inhibitor therapy for newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: primary endpoint results from the Blissphall study
1512 View	A phase i/ii study to investigate the addition of venetoclax to dasatinib and steroids in patients with newly diagnosed or relapsed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL): the Venda Trial, in progress
2827 View	Chemotherapy-free combination of blinatumomab and ponatinib in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: updates from a phase II trial
2868 View	A phase ii study of low-intensity chemotherapy (mini-hyper-cvd) and ponatinib followed by blinatumomab and ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
2869 View	Venetoclax combined with hag regimen in newly diagnosed ETP-ALL: interim analysis of a prospective, multicenter, phase 2 trial
2870 View	A phase 1 study of venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with B-cell Ph-like ALL
2871 View	Ponatinib versus imatinib in patients with newly diagnosed Ph+ all: subgroup analysis of the phase 3 Phallcon study
4205 View	Combination of olverembatinib and vp regimen as first-line therapy for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
4238 View	Updated results on a multicenter phase II study of a dose intensified pediatric regimen in adults with acute lymphoblastic leukemia: the 06-254 DFCI ALL consortium trial

4243 View	Reduced-dose chemotherapy followed by blinatumomab as induction therapy in treatment of newly diagnosed Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia - interim results from a multicenter, single-arm, phase 2 study
4245 View	Updated results from a phase II study of hyper-cvad, with or without inotuzumab ozogamicin, and sequential blinatumomab in patients with newly diagnosed B-cell acute lymphoblastic leukemia
4249 View	Comparison between dasatinib-blinatumomab vs ponatinib-blinatumomab chemo-free strategy for newly diagnosed Ph+ acute lymphoblastic leukemia patients. Preliminary results of the Gimema ALLL2820 trial
4250 View	Long-term results of the frontline dasatinib/blinatumomab protocol (d-alba, Gimema LAL2116) for adult Ph+ acute lymphoblastic leukemia

Treatment for relapsed/refractory ALL

Abstract	Title
770 View	Phase 1/2 dose-escalation/dose-expansion study of anti-cd7 allogeneic CAR-T cells (WU-CART-007) in relapsed or refractory (r/r) t-cell acute lymphoblastic leukemia/ lymphoblastic lymphoma (T-ALL/LBL)
889 View	Efficacy and safety of interleukin-6-knockdown CD19-targeted CAR T cells(ssCART-19) for relapsed/refractory B-ALL
966 View	Blinatumomab in combination with immune checkpoint inhibitors (icis) of PD-1 and CTLA-4 in adult patients with relapsed/refractory (r/r) CD19 positive B-cell acute lymphoblastic leukemia (ALL): results of a phase I study
1501 View	Venetoclax combined with azacitidine was effective and safe for relapsed/refractory T-cell acute lymphoblastic leukemia/ lymphoblastic lymphoma: preliminary results of a phase 2, multicenter trial
1502 View	Venetoclax and blinatumomab for adult patients with relapsed/refractory or mrd positive Ph-negative B-precursor all: first results of the GMALL-Bliven trial
1509 View	A phase I study of venetoclax in combination with inotuzumab ozogamicin for relapsed or refractory all in adults
2872 View	Results from the phase 1 portion of a trial of oral ixazomib combined with chemotherapy in relapsed/refractory acute lymphoblastic leukemia or lymphoma in children, adolescents and young adults: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium
3474 View	First-in-human study of the CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, b-cell acute lymphoblastic leukemia or high risk-myelodysplasia: updated safety, efficacy, pharmacokinetics and pharmacodynamics
3485 View	A multicenter study of CAR-T cell therapy for relapse of B-ALL post allogeneic stem cell transplantation

3491 View	Efficacy and safety of the second CAR-T therapy in patients with refractory/relapsed acute B-cell lymphoblastic leukemia
4242 View	A phase 1 study of CD38-bispecific antibody (XmAB18968) for patients with relapsed/refractory T-cell acute lymphoblastic leukemia
4847 View	Updated results of the phase I BALLI-01 trial of ucart22 process 2 (P2), an anti-CD22 allogeneic CAR-T cell product manufactured by cellectis biologics, in patients with relapsed or refractory (r/r) cd22+ b-cell acute lymphoblastic leukemia (B-ALL)
Lba-5 View	Revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukemia: topline efficacy and safety results from the pivotal augment-101 phase 2 study

Allogeneic transplantation

Abstract	Title
232 View	Comparable outcome after busulfan- or treosulfan-based conditioning regimen in children above 4 years of age with all undergoing allogeneic hsct. Results from the Prospective International Forum-Trial
233 View	Addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation (allo-SCT) for relapsed CD22 (+) lymphoid malignancies: long-term survival results
234 View	Short-term blinatumomab as a bridge therapy for hematopoietic stem cell transplantation in B-cell acute lymphoblastic leukemia with low leukemia burden
239 View	Cd7 chimeric antigen receptor T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation remarkably improved long-term disease-free survival in refractory/relapsed T-cell acute lymphoblastic leukemia/lymphoma
1461 View	Role of allogeneic stem cell transplantation in preventing relapse in adult BCR::ABL1-like acute lymphoblastic leukemia
2210 View	Incidence and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukemia
2234 View	How much have post-transplant outcomes improved since 2000 for patients with Philadelphia-positive acute lymphoblastic leukemia in first remission? A study from the EBMT Acute Leukemia Working Party
2235 View	Allogeneic hematopoietic stem cell transplantation for elderly acute lymphoblastic leukemia patients: a registry study from the société francophone de greffe de moelle et thérapie cellulaire (SFGM-TC)
2237 View	Prognostic factors impacting post-transplant outcomes in adult t-cell acute lymphoblastic leukemia: a registry-based study by the EBMT Acute Leukemia Working Party

2830 View	Clinical outcomes of adults undergoing allogeneic stem cell transplant for secondary acute lymphoblastic leukemia
4958 View	Outcomes and prognostic factors of second allogeneic hematopoietic cell transplantation in patients with acute lymphoblastic leukemia: a study from the Adult Acute Lymphoblastic Leukemia Working Group of the Japanese Society for Transplantation and Cellular Therapy

Real-world evidence

Abstract	Title
1029 View	Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (r/r) adult b-cell acute lymphoblastic leukemia (B-cell ALL): evidence from the CIBMTR Registry
1030 View	Brexucabtagene autoleucel in adults with relapsed/refractory B-cell all: outcomes and novel insights from the real-world outcomes collaborative of CAR T in adult all (ROCCA)
1507 View	Use of ponatinib alone or combined with other therapies in relapsed/refractory Ph-like acute lymphoblastic leukemia. A campus all real-life study
3498 View	Efficacy and tolerance of brexucabtagene autoleucel in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia : a Graall study from the Descar-T Registry

Socioeconomic challenges

Abstract	Title
493 View	Racial/ethnic disparity for hematologic malignancies in different healthcare systems in the U.S
671 View	The impact of social determinants of health on brexucabtagene autoleucel outcomes in adults with relapsed/refractory B-cell acute lymphoblastic leukemia
1468 View	Socioeconomic determinants and the biology and outcomes of acute lymphoblastic leukemia in adults
2391 View	Socioeconomic disadvantage is associated with decreased long-term survival in adolescent and young adult patients with acute lymphoblastic leukemia
2392 View	Distance to care predicts clinical trial enrollment on COG ALL clinical trials: a report from the Children's Oncology Group
5169 View	Disparities among adolescent and young adult patients with acute lymphoblastic leukemia

<p>5078 View</p>	<p>Enhanced support services including nurse navigation mitigate socioeconomic disparities in the treatment of patients with acute lymphoblastic leukemia</p>
---	---

Molecular biomarkers	
Abstract	Title
<p>495 View</p>	<p>Risk factors for CD19-targeting CAR T manufacturing failure and patient outcomes: a report from the UK National CAR T Panel</p>
<p>521 View</p>	<p>Association between high antimetabolite dose intensity during maintenance, toxicities and relapse risk in children with acute lymphoblastic leukemia (ALL): COG-AALL03N1 report</p>
<p>841 View</p>	<p>Single cell transcriptomic analysis of B-cell acute lymphoblastic leukemia (B-all) reveals correlation between leukemia cell state, genetic alterations and clinical outcome</p>
<p>844 View</p>	<p>NGS-based stratification refines the risk stratification in T-ALL and identifies a very high-risk subgroup of patients</p>
<p>1464 View</p>	<p>Achievement of undetectable BCR::ABL1 (UBCR::ABL1) is predictive of improved survival in Philadelphia chromosome positive (Ph+ve) acute lymphoblastic leukemia (ALL) patients not receiving allogeneic stem cell transplantation</p>
<p>2134 View</p>	<p>Low disease burden pre-CAR T-cell therapy for children and AYA with B-ALL is associated with an impaired outcome when obtained through intensification of the bridging therapy</p>
<p>2969 View</p>	<p>Inflammatory signatures define a new high-risk T-lineage ALL subtype</p>
<p>2970 View</p>	<p>Genomic determinants of therapy response in ETV6::RUNX1 leukemia</p>
<p>2975 View</p>	<p>Drug response profiling of childhood T-cell acute lymphoblastic leukemia to inform functional precision medicine</p>
<p>4346 View</p>	<p>The CNS microenvironment promotes leukemia cell survival by disrupting tumour suppression and cell cycle regulation in pediatric T-cell acute lymphoblastic leukemia</p>
<p>4349 View</p>	<p>Exploring the heterogeneity of response to blinatumomab in high-risk philadelphia-negative B-cell precursor acute lymphoblastic leukemia: an analysis from the quest sub-study of the Graall-2014/B trial</p>
<p>4350 View</p>	<p>Drug response profiling informs personalized bridging to cell therapy for patients with relapsed/refractory acute lymphoblastic leukemia</p>

Treatment-related toxicities	
Abstract	Title
522 View	Toxicity profile of brexucabtagene autoleucel (brexu-cel; cd19-directed CAR T-cell therapy) in adult patients (pts) with relapsed/refractory (r/r) b-cell acute lymphoblastic leukemia (B-ALL): results from a multicenter real-world outcomes study
1456 View	Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen
1459 View	Hepatitis b reactivation without hepatitis is a common event in adolescent/adult patients of acute lymphoblastic leukemia with occult hepatitis b (OHBI) treated on pediatric protocols and warrants prophylactic antivirals: a prospective cohort study
2873 View	Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia

Others	
Abstract	Title
127 View	A machine learning approach for predicting the occurrence of asparaginase-associated pancreatitis in pediatric patients with acute lymphoblastic leukemia
132 View	Development of a real-time dashboard characterizing acute leukemia clinical trial enrollment diversity at the practice, investigator, and individual clinician level
257 View	Excellent safety profile of a low-cost novel humanized cd19 CAR T-cell therapy, actalycabtagene autoleucel: potential impact on access and feasibility
417 View	Phenotypic drug response profiling identifies asparaginase-based synergistic combinations for very high risk acute lymphoblastic leukaemia
887 View	A rare cell state underpins diverse mechanisms of adaptive resistance to CAR T-cell therapy in B-cell acute lymphoblastic leukemia
3475 View	Role of microenvironment in influencing the activity of CD19 CAR T cells in B-cell precursor acute lymphoblastic leukemia (B-ALL)
3704 View	Patterns of care among adolescents and young adults treated for acute lymphoblastic leukemia: a retrospective study across diverse US practices
3760 View	Trends of obesity over time and its prognostic significance in children and adolescents with newly-diagnosed acute lymphoblastic leukemia in Canada: a population-based study



ASH 2023

Follow us on X to keep up to date
with the latest from the congress

@ALL_Hub_

#ASH23

View all @ALL_Hub_ tweets from #ASH23



Brought to you by

